ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

2:45PM-3:00PM: Abstract Number: 0983

Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Bugs & Drugs (0980–0983)

2:45PM-3:00PM: Abstract Number: 0977

Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing

Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

2:45PM-3:00PM: Abstract Number: 0973

Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants

Abstracts: SLE – Etiology & Pathogenesis (0970–0973)

3:00PM-3:15PM: Abstract Number: 0978

Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin

Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

3:15PM-3:30PM: Abstract Number: 0979

Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations

Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

3:30PM-3:45PM: Abstract Number: PP10

Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words

Patient Perspectives (PP10–PP13)

3:30PM-3:45PM: Abstract Number: 0984

Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up

Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)

3:45PM-4:00PM: Abstract Number: PP11

“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases

Patient Perspectives (PP10–PP13)

3:45PM-4:00PM: Abstract Number: 0985

Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers

Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)

4:00PM-4:15PM: Abstract Number: PP12

Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic

Patient Perspectives (PP10–PP13)

4:00PM-4:15PM: Abstract Number: 0986

Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial

Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)

4:00PM-4:15PM: Abstract Number: 0988

Risk Prediction Models for Incident Systemic Lupus Erythematosus Using Lifestyle/Environmental Risk Factors and a Genetic Risk Score

Abstracts: Epidemiology & Public Health I: Risk in Rheumatic Diseases (0988–0991)

4:15PM-4:30PM: Abstract Number: PP13

CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

Patient Perspectives (PP10–PP13)

4:15PM-4:30PM: Abstract Number: 0989

Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users

Abstracts: Epidemiology & Public Health I: Risk in Rheumatic Diseases (0988–0991)

4:15PM-4:30PM: Abstract Number: 0987

Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial

Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].